Multiple Sclerosis
From the Journals
Lack of natalizumab concentration increase before PML argues against extending dosing interval
Serum concentrations of natalizumab do not appear to rise before patients with relapsing-remitting multiple sclerosis are diagnosed with...
From the Journals
Nomogram predicts conversion of first demyelinating event to definite MS
Baseline and follow-up data from a prospective, multinational cohort of more than 3,000 patients with clinically isolated events allowed...
Literature Review
Which Factors Predict Relapse Freedom After Cessation of MS Treatment?
Patients with multiple sclerosis (MS) treated with interferon beta or glatiramer acetate who are age 45 or older and have no evidence of clinical...
Conference Coverage
What Do We Know About Pediatric MS?
BALTIMORE—Lack of evidence for disease-modifying therapies (DMTs) in children presents a significant challenge in pediatric multiple sclerosis (MS...
Literature Review
Higher Latitude Is Associated With Earlier Age of MS Onset
Among patients of European descent, higher latitude regions are associated with an earlier age at onset of multiple sclerosis (MS), according to...
Conference Coverage
Opicinumab May Benefit Patients With Relapsing-Remitting MS
LONDON—Opicinumab, an investigational remyelinating agent, may promote clinical improvement in patients with multiple sclerosis (MS) who are...
Literature Review
Alemtuzumab Reduces Preexisting MS Disability
In addition to slowing disability accumulation, alemtuzumab improves preexisting disability in patients with relapsing-remitting multiple...
Conference Coverage
Vitamin D as an Add-On Therapy May Improve MRI Outcomes in MS
LONDON—High-dose vitamin D as an add-on therapy may improve MRI outcomes in patients with relapsing-remitting multiple sclerosis (MS), according...
Article
MS relapse predictors identified after patients stop treatment
Patients with multiple sclerosis treated with interferon-beta or glatiramer acetate who are aged 45 and over and have no evidence of clinical...
Conference Coverage
How Much MS Disease Activity Is Acceptable?
LONDON—No evidence of disease activity (NEDA) is a worthy but potentially problematic goal in the care of patients with multiple sclerosis (MS),...
Conference Coverage
Lipoic Acid Reduces Brain Atrophy in Secondary Progressive MS
LONDON—Daily oral intake of 1,200 mg of racemic lipoic acid significantly reduces the rate of whole brain atrophy among patients with secondary...